三名Aura Biosciences内部人士在2026年2月17日出售了42万美元的股票, Three Aura Biosciences insiders sold $425K in stock on Feb. 17, 2026, reducing their combined stake by 8%.

2026年2月17日, 奥拉生物科学公司(Aura Biosciences-Los Pinos Elisabet De, CTO)三名内幕人士与另一名内幕人士共售出83 939股股票,平均价格为5.06美元,共计约424 672美元。 On February 17, 2026, three insiders at Aura Biosciences—Los Pinos Elisabet De, the CTO, and another insider—sold a combined 83,939 shares at an average price of $5.06, totaling about $424,672. 销售量将其合并所有权减少了8%,减至10.4%,库存量大,结盘为5.25美元,减少0.32美元。 The sales reduced their combined ownership by 8% to 10.4%, with the stock closing at $5.25, down $0.32, on heavy volume. 该公司是一家临床生物制药公司,开发治疗癌症的病毒类粒子疗法,市场上限为3.338亿美元,混合分析师评级为“Moderate Buy”,目标价格为20.50美元。 The company, a clinical-stage biopharmaceutical firm developing virus-like particle therapies for cancer, has a market cap of $333.38 million and a mixed analyst rating with a consensus "Moderate Buy" and a $20.50 target price.